Adocia announced the initiation of a Phase Ib clinical trial evaluation for BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. This formulation uses Adocia's proprietary technology BioChaperone, which is believed to enable the acceleration of insulin absorption. This is the first study to be initiated as part of the Adocia-Lilly partnership.

The study aims to measure the effect of BioChaperone Lispro, injected at the time of a standardized meal, on post-meal glycemic control in type 1 diabetes patients and compare this effect to that of Humalog (insulin lispro rDNA origin). In this crossover, randomized, double-blind study, 36 type 1 diabetes patients will receive one dose of BioChaperone Lispro and one dose of Humalog when taking a standardized meal. The main objective of this study is to compare post-meal glycemic control obtained after the injection of either BioChaperone Lispro or Humalog.

The pharmacokinetic profiles of both products will also be monitored.